Back to Search
J GULLEY, PHARMD
PHARMD
Pharmacist
NPI: 1528620069Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
03131822(OH)
Research & Publications (20)
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
PMID 19495750·Cancer Immunol Immunother·2010
8-other
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
PMID 19451403·J Clin Pharmacol·2009
3-trial
Combining radiation and immunotherapy for synergistic antitumor therapy.
PMID 19169958·Curr Opin Mol Ther·2009
6-review
Reduced sensitivity to the locomotor-stimulant effects of cocaine is associated with increased sensitivity to its discriminative stimulus properties.
PMID 19125118·Behav Pharmacol·2009
7-preclinical
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
PMID 19154507·BJU Int·2009
3-trial
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
PMID 19548854·Expert Opin Investig Drugs·2009
6-review
Promising novel immunotherapies and combinations for prostate cancer.
PMID 19284377·Future Oncol·2009
6-review
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
PMID 19235596·Cancer Invest·2009
3-trial
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
PMID 19167733·J Urol·2009
2-rct
Cancer vaccines: current directions and perspectives in prostate cancer.
PMID 19169957·Curr Opin Mol Ther·2009
6-review
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
PMID 18628467·Clin Cancer Res·2008
3-trial
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.
PMID 18777956·Oncology (Williston Park)·2008
6-review
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
PMID 18710748·J Urol·2008
3-trial
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
PMID 18423743·J Urol·2008
6-review
Therapeutic prostate cancer vaccines: a review of the latest developments.
PMID 19037836·Curr Opin Investig Drugs·2008
6-review
Disparate cocaine-induced locomotion as a predictor of choice behavior in rats trained in a delay-discounting task.
PMID 18539407·Drug Alcohol Depend·2008
4-observational
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
PMID 18537956·BJU Int·2008
8-other
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
PMID 18483372·Clin Cancer Res·2008
5-case
Dissociation between long-lasting behavioral sensitization to amphetamine and impulsive choice in rats performing a delay-discounting task.
PMID 18473112·Psychopharmacology (Berl)·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 460 W 10TH AVE
COLUMBUS, OH 43210 - Phone
- (614) 293-3312
Quick Facts
- NPI
- 1528620069
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile